133(top 1%)
papers
1.5K(top 2%)
citations
12(top 2%)
h-index
39(top 1%)
g-index
136
all documents
1.7K
doc citations
572
citing journals

Top Articles

#TitleJournalYearCitations
1Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trialsAnnals of Oncology2017654
2Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 studyThe Lancet Gastroenterology and Hepatology2021205
3FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancerEuropean Journal of Cancer2015202
4Cancer Dormancy: A Model of Early Dissemination and Late Cancer RecurrenceClinical Cancer Research2012173
5<p>Current status of liquid biopsies for the detection and management of prostate cancer</p>Cancer Management and Research201947
6The importance of surgical margins in breast cancerJournal of Surgical Oncology201637
7Surgery and adjunctive chemotherapy for invasive bladder cancerSurgical Oncology200231
8Chemotherapy and cystectomy for invasive transitional cell carcinoma of bladderUrologic Oncology: Seminars and Original Investigations200328
9Development and Application of Liquid Biopsies in Metastatic Prostate CancerCurrent Oncology Reports201828
10Phase II trial of continuous treatment with sunitinib in patients with high-risk (BCG-refractory) non-muscle invasive bladder cancerInvestigational New Drugs201922
11AXIN2 expression predicts prostate cancer recurrence and regulates invasion and tumor growthProstate201614
12Frequency of BRCA mutation in biliary tract cancer and its correlation with tumor mutational burden (TMB) and microsatellite instability (MSI).Journal of Clinical Oncology201912
13Association of BRCA-mutant pancreatic cancer with high tumor mutational burden (TMB) and higher PD-L1 expression.Journal of Clinical Oncology201912
14Pharmacogenomics and metastatic colorectal cancer: Current knowledge and perspectivesScandinavian Journal of Gastroenterology201211
15Baseline Glomerular Filtration Rate and Cisplatin- Induced Renal Toxicity in Urothelial Cancer PatientsClinical Genitourinary Cancer201811
16Malignancy rates after surgical excision of discordant breast biopsiesJournal of Surgical Research201510
17Leptomeningeal carcinomatosis in sinonasal undifferentiated carcinomaHead and Neck20139
18Impact of timing of administration of bone supportive therapy on pain palliation from radium-223Cancer Treatment and Research Communications20199
19Clinical value of atezolizumab + bevacizumab for first-line unresectable hepatocellular carcinoma (HCC): A network meta-analysis.Journal of Clinical Oncology20208
20Characteristics of patients (pts) with metastatic colorectal cancer (mCRC) treated with regorafenib (REG) who had progression-free survival (PFS) >4 months (m): Subgroup analysis of the phase 3 CORRECT trialAnnals of Oncology20167
21GDF15 expression in metastatic colorectal cancer.Journal of Clinical Oncology20217
22Molecular landscape of colorectal cancers harboring R-spondin fusions.Journal of Clinical Oncology20197
23A phase II, open-label study of tomivosertib (eFT508) added on to continued checkpoint inhibitor therapy in patients (pts) with insufficient response to single-agent treatment.Journal of Clinical Oncology20207
24Comprehensive molecular profiling of IDH1/2 mutant biliary cancers (BC).Journal of Clinical Oncology20207
25‘Active surveillance’ for stage I testis cancerEuropean Journal of Cancer20006
26High CXCR4 expression in pancreatic ductal adenocarcinoma as characterized by an inflammatory tumor phenotype with potential implications for an immunotherapeutic approach.Journal of Clinical Oncology20216
27The landscape of DNA damage response (DDR) pathway in colorectal cancer (CRC).Journal of Clinical Oncology20206
28Characteristics of colorectal cancer (CRC) patients with BRCA1 and BRCA2 mutations.Journal of Clinical Oncology20195
29Chemotherapy for Good-Risk Nonseminomatous Germ Cell TumorsUrologic Clinics of North America20154
30Chemotherapy for oligometastatic prostate cancerCurrent Opinion in Urology20174
31Health-related Quality of Life in the Phase III LUME-Colon 1 Study: Comparison and Interpretation of Results From EORTC QLQ-C30 AnalysesClinical Colorectal Cancer20194
32MORPHEUS: A phase Ib/II trial platform evaluating the safety and efficacy of multiple cancer immunotherapy (CIT) combinations in patients (pts) with gastric or pancreatic cancer.Journal of Clinical Oncology20184
33Genetic variations within the CD40L immune stimulating gene predict outcome for mCRC patients treated with first-line FOLFIRI/bevacizumab: Data from FIRE-3 and TRIBE.Journal of Clinical Oncology20194
34Circulating tumor cells in prostate cancer: a better predictor of survival than prostate specific antigen?Expert Review of Anticancer Therapy20143
35Single nucleotide polymorphisms (SNPs) in endoplasmic reticulum (ER) stress response genes to predict first-line treatment outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from the MAVERICC and FIRE-3 trials.Journal of Clinical Oncology20213
36Genetic variants of ATM and XRCC3 to predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer.Journal of Clinical Oncology20163
37Polymorphisms in toll-like receptor (TLR) genes in the prediction of outcome for cetuximab-based treatment in patients with metastatic colorectal cancer (mCRC).Journal of Clinical Oncology20163
38BRCA1 genetic variant to predict survival in metastatic colorectal cancer (mCRC) patients (pts) treated with FOLFIRI/bevacizumab (bev): Results from phase III TRIBE and FIRE-3 trials.Journal of Clinical Oncology20193
39Gene mutations of SWI/SNF complex and molecular profile in colorectal cancer.Journal of Clinical Oncology20193
40A phase I/II multisite study of nivolumab and carboplatin/paclitaxel with radiation therapy (RT) in patients with locally advanced esophageal squamous cell carcinoma (ESCC).Journal of Clinical Oncology20203
41Selecting the best targeted agent in first‐line treatment of unresectable liver metastases from colorectal cancer: does the bench have the answers?Journal of Hepato-Biliary-Pancreatic Sciences20122
42Identification and prognostic impact of PBRM1 mutations in biliary tract cancers: Results of a comprehensive molecular profiling study.Journal of Clinical Oncology20212
43Genetic variants of hENT-1 to predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer.Journal of Clinical Oncology20162
44Role of genetic polymorphisms in CCL5/CCR5 axis to predict efficacy of regorafenib in patients with refractory metastatic colorectal cancer.Journal of Clinical Oncology20172
45Circadian clock gene PER1 mutations in colorectal cancer (CRC).Journal of Clinical Oncology20182
46Polymorphism in the circadian clock pathway to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from TRIBE and FIRE-3 phase III trials.Journal of Clinical Oncology20182
47Phase II multicenter pilot study of safety, efficacy, and immune cell profiling in advanced hepatocellular carcinoma (HCC) on combination of sorafenib (SOR) plus nivolumab (NIVO).Journal of Clinical Oncology20192
48AGEN1181, a clinical stage Fc-engineered anti-CTLA-4 antibody with improved therapeutic potential for the treatment of patients with advanced malignancies.Journal of Clinical Oncology20202
49Genetic variants in immune response genes to predict clinical outcome in mCRC patients treated with FOLFIRI/cetuximab (FIRE-3) or with first line cetuximab-based chemotherapy (JACCRO CC-05/06 AR).Journal of Clinical Oncology20162
50Urethral Cancer20061